Skip to Main Content

Good morning, everyone, and how are you today? We are doing just fine, thank you, despite the general uncertainty these days. After all, the birds are still chirping and a cool breeze is wafting by. Moreover, this marks the middle of the week, which means we have managed to persevere this far. And this calls for celebration, yes? So please join us as we hoist another cup of delicious stimulation. Remember, no prescription is required. Meanwhile, here are a few items of interest. Have a grand day, and drop us a line if you hear something saucy. …

The European Commission called for global leaders to cooperate to buy bulk quantities of potential Covid-19 vaccines to avoid “harmful competition” and ensure any future vaccine is available to poor countries, Reuters reports. With a dozen potential vaccines now in human trials, rich countries are rushing to buy doses in advance from drug makers to ensure supplies should any prove successful. The European Commission is worried this could raise prices for everyone and also leave many countries, mostly poor ones, struggling to obtain a supply.


Sanofi (SNY) pledged to invest more than $675 million in vaccine research and production in France in response to a demand from President Emmanuel Macron that his country have access to any vaccine the French drug maker develops against Covid-19, The Wall Street Journal writes. As countries from the U.S. to China jockey to secure supplies of future coronavirus vaccines, they are fueling what public-health experts call “vaccine nationalism,” a geopolitical race to become the first country to immunize its population.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!